NGS Streamlines Biomarker Testing in Solid Tumors
Next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors, according to Chen, PharmD, MS, BCOP, CPP.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, discuss the benefits of NGS.
- Mark Agulnik, MD, Mrinal M. Guckerman, MD, and others share insights on NGS in solid tumors.
- Additional experts, such as Naval G. Daver, MD, and Jessica Altman, MD, contribute to the discussion.
Experts discuss how NGS improves biomarker testing and treatment planning.
Authors include Chen, Traina, Smith-Graziani, Agulnik, and many others.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- Forever Canadian petition rumoured to have collected more than 300,000 pro-Canada signatures – daveberta.ca – Alberta Politics and Elections
- Australia’s reduction roadmap calls for a 99 percent cut in new housing emissions
- The UK needs regulation – but we can do it an awful lot better
- Lawmakers face conflicting calls to loosen, tighten regulation of hemp and marijuana